"Xuanzhu Biopharmaceutical Successfully Lists on Hong Kong Stock Exchange, Raising HKD 781 Million"

"DLA Piper has advised on the successful global offering and listing of Chinese biotech company Xuanzhu Biopharmaceutical on the Hong Kong Stock Exchange, raising approximately HKD781 million (USD100.4 million). The offering was highly popular, being oversubscribed by over 4,900 times. This listing allows Xuanzhu to focus on its innovative drug development after spinning off from its parent company, Sihuan Pharmaceutical. Xuanzhu, established in 2008, has a strong R&D platform and is developing over ten drug assets targeting various diseases. DLA Piper's team, led by George Wu, expressed confidence in Xuanzhu's growth and the strength of Hong Kong's capital markets."

DLA Piper has advised the sole sponsor and underwriters in the global offering and listing of Xuanzhu Biopharmaceutical, a Chinese biotech company, on the Main Board of the Hong Kong Stock Exchange (HKEX). The transaction involved raising approximately HKD781 million (around USD100.4 million) through a public offering that was oversubscribed by over 4,900 times, making it one of the most popular new listings of the year. This listing represents a spin-off of Xuanzhu Biopharmaceutical from its parent company, Sihuan Pharmaceutical Holdings Group, and provides Xuanzhu with enhanced financial flexibility and a dedicated platform for innovative drug development. The DLA Piper team was led by George Wu, Co-Head of Equity Capital Markets EMEA and Asia Pacific. Supporting him were senior associate Jack Li, registered foreign lawyer Jessica Sun, associate Marcus Ng, legal assistant Nicholas Chan, legal officer Ivy Chung, and trainee solicitor Bernie Wong. Additional support came from legal assistants Charlotte Wang and Jack Du in Shanghai.

"Xuanzhu Biopharmaceutical Successfully Lists on Hong Kong Stock Exchange, Raising HKD 781 Million"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads